Well that's a step up! At least now you're predicting the successful completion of the TOX studies, although in a time frame about three times what will likely be the case.
This estimate for start to finish is so far outside of reality for any drug--unless it fails nonclinical safety, has to be reformulated, and then retested nonclinically--is so far off it's actually laughable.
News 
Market Data 
Discover 
